Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Coya Therapeutics (NASDAQ:COYA) with a maintained price target of $14.

April 29, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on Coya Therapeutics with a $14 price target.
The reiteration of a Buy rating and a $14 price target by a reputable analyst like Keay Nakae from Chardan Capital is likely to instill confidence among investors and could lead to a positive short-term impact on COYA's stock price. Analyst ratings, especially with a Buy recommendation, often signal market confidence in the company's future performance, potentially influencing investor sentiment and stock price movement.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100